<DOC>
	<DOCNO>NCT00035230</DOCNO>
	<brief_summary>The primary purpose study evaluate safety efficacy topiramate compare placebo treatment acute manic mixed episodes patient Bipolar I Disorder .</brief_summary>
	<brief_title>A Study Safety Efficacy Topiramate Treatment Patients With Bipolar I Disorder</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled study evaluate safety efficacy topiramate ( 400 milligrams/day ) compare placebo treatment acute manic mixed episodes patient Biplar I Disorder . In addition , third group patient treat lithium ( 1500milligrams/day ) comparator drug . The trial consist 3 phase : screening period ; double-blind treatment 12 week ; optional open-label period least 6 month . Efficacy assessment include change baseline Day 21 Young Mania Rating Scale ( YMRS ) score . Also include efficacy assessment 12 week study Clinical Global Impressions ( CGI ) scale , Global Assessment Scale ( GAS ) , Montgomery-Ã…sberg Depression Rating Scale ( MADRS ) , Brief Psychiatric Rating Scale ( BPRS ) , health-related quality life measure specify time interval . Safety assessment include evaluation adverse event throughout study , rate withdrawal study due adverse event , vital sign ( blood pressure pulse ) througout study , well change clinical laboratory test ( hematology , chemistry , urinalysis ) , electrocardiogram ( ECGs ) , physical examination specify time . The study hypothesis change baseline total Young Mania Rating Scale ( YMSR ) score Day 21 significantly good topiramate group placebo group study drug well tolerated patient . Topiramate oral capsule increase daily ( 50mg ) 3 time daily target total daily dose 400mg , maintain Week 12 . Lithium oral capsule increase daily ( 300mg ) 3 time daily target total daily dose 1500mg , maintain Week 12 .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<criteria>Diagnosis Bipolar I Disorder criterion Diagnostic Statistical Manual Mental Diseases , 4th edition ( DSMIV ) confirm Structured Clinical Interview DSMIV Axis I Disorders ( SCIDI ) Currently manic mixed episode least one previous manic mixed episode meet minimum severity criterion ( Young Mania Rating Scale [ YMRS ] score &gt; =20 screen baseline visit ) current acute manic mixed episode Females must postmenopausal , surgically sterile , use adequate contraceptive measure , negative pregnancy test DSMIV diagnosis alcohol substance dependence ( exception nicotine caffeine dependence ) DSMIV Axis I diagnosis schizoaffective disorder impulse control disorder Experienced manic episode take antidepressant psychostimulant drug know hypersensitivity topiramate previously participate topiramate study</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Bipolar disorder</keyword>
	<keyword>Bipolar</keyword>
	<keyword>mania</keyword>
	<keyword>Topiramate</keyword>
	<keyword>Lithium</keyword>
</DOC>